Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

December 31, 2010

Study Completion Date

September 12, 2017

Conditions
LeukemiaLymphoma
Interventions
BIOLOGICAL

Rituximab

Cycle 1: 100 mg by IV on day 1, 375 mg/m\^2 by IV on day 2 Cycle 2-6: 375 mg/m\^2 by IV on day 1 (every 21 days)

DRUG

Cyclophosphamide

600 mg/m\^2 by IV on day 1 of cycles 1-6 (every 21 days)

DRUG

Lenalidomide

Cycle 7: 5 mg orally daily on days 1-28 Cycle 8: 10 mg orally daily on days 1-28 as tolerability permits Cycle 9 and beyond: 10 mg orally daily on days 1-28

DRUG

Pentostatin

2 mg/m\^2 by IV on day 1 of cycles 1-6 (every 21 days)

Trial Locations (3)

32224

Mayo Clinic - Jacksonville, Jacksonville

55905

Mayo Clinic Cancer Center, Rochester

85259-5499

Mayo Clinic Scottsdale, Scottsdale

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER